mTOR Inhibitors and Healthspan: A Careful Reading of the Evidence
A structured review of pharmacological interventions targeting mTOR pathways in the context of healthy aging.
Interest in mTOR-modulating interventions has grown rapidly. The clinical picture, however, remains more nuanced than public discussion suggests.
This review focuses on evidence relevant to healthy adults, not disease indications where the risk-benefit profile differs substantially.
We examine study design, endpoints, adverse-event patterns, and unresolved questions.
Recommendations for clinical practice are conservative and specify the conditions under which further research would change our view.
Key findings
- Effect sizes vary substantially across studies.
- Applicability to healthy adults remains contingent on further evidence.
- Careful monitoring is warranted when interventions are used off-label.
Clinical context
Recommendations should always be considered within the individual patient's clinical picture.
Limitations
Publication bias, heterogeneous protocols, and short follow-up limit strong conclusions.
References
- Author et al. Journal Placeholder. Year. Volume, Pages.
- Author et al. Journal Placeholder. Year. Volume, Pages.
Comments
Sorted by most relevant · Moderated by editorial staff.